BioRender Icon

Neuroblastoma (SH-SY5Y, apoptosis, blebbing)

Neuroblastoma (SH-SY5Y, apoptosis, blebbing) - Editable icon of A differentiated SH-SY5Y neuroblastoma with a budding axon and a pyramidal body, blebbing and undergoing apoptosis
[{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68f6/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68f6/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68f5/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68f5/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68f4/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68f4/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68f3/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68f3/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68f2/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68f2/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68f1/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68f1/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68f0/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68f0/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68ef/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68ef/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68ee/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68ee/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68ed/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68ed/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68ec/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68ec/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68eb/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68eb/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68ea/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68ea/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e9/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e9/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e8/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e8/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e7/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e7/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e6/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e6/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e5/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e5/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e4/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e4/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e3/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e3/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e2/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e2/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e1/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e1/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e0/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e0/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68df/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68df/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68de/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68de/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68dd/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68dd/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68dc/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68dc/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68db/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68db/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68da/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68da/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d9/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d9/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d8/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d8/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d7/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d7/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d6/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d6/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d5/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d5/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d4/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d4/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d3/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d3/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d2/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d2/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d1/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d1/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d0/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d0/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68cf/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68cf/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68ce/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68ce/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68cd/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68cd/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68cc/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68cc/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68cb/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68cb/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68ca/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68ca/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68c9/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68c9/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68c8/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68c8/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68c7/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68c7/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68c6/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68c6/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68c5/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68c5/630633e17c75bb00281a685f.png"}]
Use This Icon – Free
No credit card required to sign up.

This icon is fully editable in BioRender

  • Add text, shapes, & other icons
  • Search 50,000+ scientifically accurate icons
  • Recolor and rearrange every icon, line, & label
  • Export or share for any use case
Scientist Avatars

Join 4M+ scientists already making publication-ready figures

Go from icons to finished figure – in minutes

  • Search from 50,000+ scientifically accurate, peer-reviewed icons
  • Customize with labels, shapes, and additional icons – everything is completely editable
  • Export or share your figures with collaborators

Not quite the right icon? Discover more.

Search 50,000+ icons across 30+ life-science fields.

search icon
arrow-right
Keywords
neuroblastoma,apoptosis,blebbing,cell death,programmed cell death,nuclear fragmentation,necrosis,capsase,protease,degradation,atrophy,SH-sy5y,SK-N-SH,parkinson,neurogenesis,differentiated,differentiation,n type,SH-sy5y
View More

Try a synonym, or sign up to request an icon from the app.

Image types

Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon JPEG

Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon PNG

Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon SVG

Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon GIF

Biorender Icon FAQs

How are scientists using the Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon in their work?

BioRender users often use the Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Cell Types.

Can I use this icon in a BioRender figure or scientific illustration?

Yes, the Neuroblastoma (SH-SY5Y, apoptosis, blebbing) is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon customizable in BioRender?

Most icons in BioRender, including the Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

Can I export figures that include the Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon for publication or presentations?

Yes, figures containing the Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

How do I cite BioRender if I use this icon?

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

Is the Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon — especially those focused on Cell Types. You can search BioRender’s template library or add this icon manually to any canvas.

What is BioRender?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon along with our library of more than 30,000 life science icons.

Looking for science content?

Browse 50K+ icons and templates that are peer-reviewed, easy to use, and free.

Find yours now
x icon